Related coverage linked through entity extraction aliases.
Apr 16, 2026
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
Apr 16, 2026
A new Cochrane review said anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit, but many researchers said the analysis has major limitations. Newer evidence on lecanemab and donanemab and broader drug development efforts continue to shape the field.
Apr 16, 2026
A review of 17 studies involving 20,342 patients found anti-amyloid Alzheimer’s drugs had “trivial” effects after 18 months and increased the risk of brain swelling and bleeding. A separate PET study suggested ARIA-E may mark brain regions with greater amyloid plaque reduction.
Apr 10, 2026
Deep learning studies using MRI, genetics and longitudinal imaging reported improved dementia risk prediction and mapped dynamic brain-region changes during Alzheimer’s disease progression.
Apr 07, 2026
NeuroTherapia has completed a Phase 2a trial of NTRX-07 in Alzheimer's patients, meeting safety objectives with no treatment-related serious adverse events. Preliminary biomarker analysis shows encouraging results, including MRI findings trending toward stabilization. The oral small molecule targets neuroinflammation and showed positive effects in animal models.
Apr 07, 2026
CervoMed presents new MRI data showing neflamapimod may reduce basal forebrain atrophy in dementia with Lewy bodies and finalizes Phase 3 trial design. The drug has also been selected for a UK-funded ALS platform trial, with first dosing expected by end of 2026.
Apr 07, 2026
A cortical tri-culture model using human iPSC-derived neurons and astrocytes has been validated for neurodegenerative drug discovery and neurotoxicity screening. The model successfully identified compound modes of action in blinded testing, addressing a critical need for physiologically relevant cortical models. Neurodegenerative diseases affect approximately 15% of the global population, with prevalence expected to increase with aging populations.
Apr 07, 2026
Multiple therapeutic approaches targeting the APOE4 gene are advancing, including small molecule drugs, gene therapies, and repurposed medications. The APOE4 variant confers a 60% lifetime Alzheimer's risk and affects brain metabolism, increasing seizure susceptibility. Research shows blood pressure drug terazosin can reduce seizures in APOE4 models by boosting cellular energy production.
Apr 02, 2026
Genomic technologies including whole-genome sequencing and polygenic risk scores are advancing precision medicine for neurodegenerative diseases like Alzheimer's and Parkinson's. Research reveals complex gene interactions in conditions like PTEN hamartoma tumor syndrome and sex-specific metabolic signatures in Alzheimer's disease. The integration of genomics with molecular neurobiology offers potential for more accurate diagnosis and treatment.
Mar 25, 2026
NICE has upheld appeals to review its guidance on Alzheimer's drugs lecanemab and donanemab, sending the decision back to committee. The manufacturers argued NICE failed to account for the treatments' wider impact on unpaid carers. This comes amid broader challenges in neurodegenerative disease research following recent high-profile clinical trial failures.
Mar 25, 2026
Researchers have identified DOPA decarboxylase as a quantitative biomarker in cerebrospinal fluid that improves diagnosis of Parkinson's disease and Lewy body dementia. The protein levels are up to 2.5 times higher in affected patients and can differentiate these conditions from Alzheimer's disease. The discovery provides clinicians with an objective diagnostic tool for conditions that are frequently misdiagnosed due to overlapping symptoms.
Mar 24, 2026
New research reveals significant advances in blood-based biomarkers for Alzheimer's disease, including a pTau 217 assay showing 93% agreement with amyloid PET imaging and identification of interferon gamma as a diagnostic signal linked to genetic risk. These developments address challenges in early diagnosis and monitoring while requiring substantially less plasma than previous tests.
Mar 22, 2026
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Mar 20, 2026
Northwestern University researchers found that levetiracetam, an FDA-approved anti-seizure medication, prevents formation of toxic amyloid-beta 42 peptides in the brain, offering a potential strategy for early Alzheimer's prevention.
Mar 17, 2026
Recent research identifies novel genetic causes for rare movement and neurodegenerative disorders, including CD99L2 variants in spastic ataxia, PPP2R5C as an Alzheimer's biomarker, and toxic polyglycine proteins in GGC repeat expansion diseases.
Mar 16, 2026
Northwestern Medicine scientists discovered that N-acetyl-L-leucine (NALL), an FDA-approved compound, promotes neuroprotective effects in experimental Parkinson's disease models by targeting multiple molecular pathways simultaneously.
Mar 14, 2026
Researchers at the University of Toronto have discovered that progressive supranuclear palsy has distinct molecular subtypes based on tau protein distribution, opening pathways for precision medicine approaches to treat this fatal neurodegenerative disease.
Mar 13, 2026
Recent studies demonstrate that blood-based biomarkers combined with AI can predict dementia risk 25 years early in women, identify liver cancer-prone environments with 93% accuracy, and classify prediabetes risk groups with 90% accuracy.
Mar 06, 2026
The global nuclear medicine equipment market is projected to reach USD 10.00 billion by 2035, driven by rising cancer prevalence, technological advances in hybrid imaging systems, and AI integration in diagnostic workflows.
Mar 05, 2026
AbbVie has successfully transitioned from Humira dependence to growth driven by Skyrizi and Rinvoq, while maintaining a 54-year dividend increase streak and expanding its pipeline to roughly 90 programs through strategic acquisitions.
